BMCM
IDXX icon

Bryn Mawr Capital Management’s Idexx Laboratories IDXX Stock Holding History

Bryn Mawr Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.35M Sell
10,158
-110
-1% -$61.7K 0.23% 100
2026
Q1 		$5.77M Sell
10,268
-68
-0.7% -$43.6K 0.28% 86
2025
Q4 		$6.99M Sell
10,336
-493
-5% -$336K 0.34% 74
2025
Q3 		$6.92M Sell
10,829
-423
-4% -$257K 0.34% 77
2025
Q2 		$6.03M Buy
11,252
+1,051
+10% +$503K 0.33% 75
2025
Q1 		$4.28M Sell
10,201
-12
-0.1% -$5.21K 0.26% 92
2024
Q4 		$4.22M Sell
10,213
-409
-4% -$179K 0.23% 95
2024
Q3 		$5.37M Sell
10,622
-23
-0.2% -$11.2K 0.29% 81
2024
Q2 		$5.19M Sell
10,645
-10
-0.1% -$5.02K 0.29% 82
2024
Q1 		$5.75M Sell
10,655
-23
-0.2% -$12.6K 0.33% 76
2023
Q4 		$5.93M Buy
10,678
+80
+0.8% +$37.6K 0.37% 70
2023
Q3 		$4.63M Buy
+10,598
New +$5.28M 0.3% 76

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bryn Mawr Capital Management's IDXX Position: Q2 2026 in Review

Bryn Mawr Capital Management reduced its Idexx Laboratories (IDXX) stake by 1.1% in Q2 2026, selling an estimated $61.7K and leaving 10,158 shares worth $5.35M. The position accounts for 0.23% of the portfolio, ranked #100.

Bryn Mawr Capital Management first reported a position in IDXX in Q3 2023 and has held it in 12 quarters since. The position peaked at $6.99M in Q4 2025. 1,295 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Bryn Mawr Capital Management held 10,158 shares of Idexx Laboratories worth $5.35M as of Q2 2026.
  • Bryn Mawr Capital Management sold 110 Idexx Laboratories shares in Q2 2026, an estimated $61.7K.
  • Idexx Laboratories made up 0.23% of Bryn Mawr Capital Management's portfolio in Q2 2026, its #100 holding.
  • Bryn Mawr Capital Management first reported a position in Idexx Laboratories in Q3 2023 and has held it in 12 quarters since.
  • Bryn Mawr Capital Management's Idexx Laboratories position peaked at $6.99M in Q4 2025.
  • 1,295 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.